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 INTRODUCTION
NaV1.5 is an integral membrane protein and tetro-
dotoxin-resistant voltage-gated Na+ channel subunit.
NaV1.5, found primarily in the cardiac muscle, 
where it mediates the fast infl  ux of Na+-ions (INa) across 
the cell membrane, resulting in the fast depolarization of 
phase 0 of the cardiac action potential (AP). As such, it 
plays a major role in impulse propagation. These chan-
nels consist of heteromeric assemblies of an α-subunit, the 
pore-forming component, the function of which is modu-
lated by association with one or two ancillary β-subunits.
The human cardiac Na+ channel α-subunit is a 
heavily glycosylated protein of ≈260 kDa consisting of 
2016 amino acid residues. It is encoded by the SCN5A 
gene, which is located on chromosome 3p21. The protein 
encoded by this gene is an integral membrane protein and 
tetrodotoxin-resistant voltage-gated sodium channel sub-
unit. This protein is found primarily in the cardiac muscle 
and is responsible for the initial upstroke phase 0 of the AP 
in an electrocardiogram.
They display a modular architecture, which con-
sists of four internally homologous domains (DI–DIV) 
each made up of six transmembrane segments (S1–S6). 
The interdomain linkers and the N- and C-terminal ends 
of the channel protein are all located cytoplasmically. 
NaV1.5.SCN5A is the gene that encodes the cardiac Na
+ 
channel NaV1.5. Mutations may act as a disease modifi er, 
especially in families where lack of direct causality is re-
fl ected by complex inheritance patterns.
A  signifi cant amount of individuals (2-7%) in 
the general population carry a rare (population frequen-
cy < 1%), protein-altering variant in the gene,
highlighting the complexity of linking mutations directly 
with observed phenotypes. Mutations that result in the 
same biophysical effect can give rise to different diseases. 
Loss-of-function mutations have been associated with 
Brugada syndrome (BrS), Progressive Cardiac Conduc-
tion Disease (PCCD) or Lenègre disease, variant 3 of long 
QT syndrome (LQT3), Idiopathic Ventricular Fibrillation 
(IVF), Early Repolarization Syndromes (ERS), Dilated 
Cardiomyopathy (DCM), sinus node dysfunction, Sick 
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cardiac impulse, excitability, excitation-contraction cou-
pling, and it is the site of action of class IA, IB and IC 
antiarrhythmic drugs. Na+ channels mediate fast depolar-
ization in nerves, skeletal muscle, working myocardium, 
and in the His-Purkinje system
 Voltage-gated Na+ channels are essential for the 
amplitude and upstroke velocity of the cardiac AP, which 
is an important determinant for impulse propagation, and 
impulse conduction velocity throughout the working myo-
cardium1 (Figure 1).
Na+ channel acts on both atrial (P wave) and ven-
tricular (QRS) depolarization. When it is open, Na+ en-
ters abruptly into the intracellular medium during phase 
0 inverting cell potential (depolarization). Additionally, 
cardiac contractility largely regulated through transient 
currents in intracellular Ca2+ concentration [Ca2+]i. [Ca2+]
i is under the infl uence of the sarcolemmal Na+/ Ca2+ ex-
changer that exchanges Ca2+ for Na+ and which is mainly 
regulated by the intracellular Na+ concentration ([Na+]
i). Consequently, [Na+]i infl uences cardiac contractil-
ity. [Na+]i is regulated by numerous proteins: Na+/K+
adenosine triphosphates (ATPases), Na+ - channels and
Na+/H+ exchangers that control and are controlled by [Na+]
i. In particular, the Na+/ K+ATPase and its crosstalk with the 
other proteins controls the intracellular level of Na+. Evi-
dence suggests that the Several Transport proteins have 
altered activity and expression patterns and this could par-
tially explain the reduced contractility in heart failure. A 
better understanding of the control of [Na+]i may lead to a 
new therapy for heart failure2.
 Na+ channels are complex molecules of about 
240-260 kDa, with the cardiac channel being about 40%
different from the nerve channel3.
Rapid depolarization in fast fi bers of phase 0 or 
upstroke of the AP is the sudden reversal of membrane 
potential that occurs when a normal atrial or ventricular 
cell reaches threshold potential at –70 to –55 mV. 
A normal cardiac cell at rest has a transmembrane 
potential of –80 to –95 mV in Na+ -channel-dependent fast 
fi bers. The gradient is maintained by pumps, especially 
Na+-KATPase, and fi xed anionic charges within the cell (in 
this process, amphoteric protein macromolecules are in-
volved). There are both electrical (Table 1) and chemical 
concentration gradients, which move Na+ through resting 
cell membranes. Table 1 (normal concentration of sodium 
in extracellular and intracellular fl uids); and table 2  (the 
conduction velocity in the different regions of the heart).
Sinus Syndrome (SSS), Sudden Infant Death Syndrome 
(SIDS), Sudden Unexplained Nocturnal Death Syndrome 
(SUNDS), Familial Atrial Fibrillation (FAF), Multifocal 
Ectopic Purkinje-related Premature Contractions (MEP-
PC) and overlapping syndromes or mixed phenotypes. 
The aim of this study was to contextualize and review the 
structure of the sarcolemmal channel and the regulation 
of one of the functional properties of the organ: conducti-
bility or dromotropism along the cardiac structures.
 METHODS
This is a literature review study, the purposes of 
which are to build a context to the problem and an analysis 
of the possibilities present in the literature to design the 
theoretical research framework.
This article was organized from scientifi c sources 
available in the database (Pubmed, Scielo, Virtual Health 
Library, Virtual Library of theses, dissertations) and sourc-
es of dissemination of ideas (journals, websites, videos, 
etc.), with analysis of each material and the development 
of tests to contextualize, for questioning and an initial 
validation of the theoretical framework used in research in 
the fi eld of channel diseases.
Thus, the conceptual analysis is enhanced and it 
allowed us to establish relationships with previous pro-
ductions, identifying recurring themes, pointing out new 
perspectives, consolidating an area of knowledge and 
constituting didactic and pedagogical practices guidelines 
for a defi nition of professional training parameters in the 
area of Health Sciences and to update the scenario of phy-
siological sciences.
ION EXTRACELLULAR INTRACELLULAR RATIO
Na+ 145 mEq/l 15 mEq/l 9.7
The conduction velocity of fast fi bers (Na+ channel dependent) is be-
tween 0.3 to 5 m/s.
Table 1: Normal concentration of sodium in extracellular and 
intracellular fl uids
Among cardiac cells, Purkinje fi bers have the high-
est concentration of Na+ channels, reaching almost one 
million per cell 4. In the cardiac Purkinje fi bers, two differ-
ent populations of Na+  channels exist with two different 
modes of operation for each one: the fi rst is responsible 
for rapid depolarization, phase 0 or upstroke of AP, and 
Figure 1: The action potential of a fast fi ber, its phase 0 and the 
entry of  the sodium cation by sodium channel.
 RESULTS AND DISCUSSION
Sodium channel characteristics
Voltage-gated Na+ channels are transmembrane 
proteins that produce the ionic current responsible for 
the rising phase of the cardiac action AP and play a 
fundamental role in the initiation, propagation, and 
maintenance of normal cardiac rhythm. The Na+ channel 
has the following functions: it allows conduction of the 
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Molecular structure of the cardiac Na+ channel: 
main α-subunit (Nav1.5) and the -β1- β2 subunits of the 
cardiac Na+ channel. The β-subunit consists of one single 
transmembrane segment. The four domains (DI-DIV) with 
6 transmembrane segments (1-6) of Nav1.5 fold around 
an ion-conducting pore. The expression and function of 
Nav1.5 is regulated by β-subunits and several directly or 
indirectly interacting regulatory proteins and β subunits of 
Na+ channels.
Alpha (α) and beta (β) subunits
The genomic organization of the cardiac sodium 
channel gene (SCN5A) has recently been described.
The three functional states of sodium channel: 
closed, open, and the inactivated state:
The Na+ fast channels have two gates in the gated 
system hypothesis - designated as “m” (activation) and 
“h” (inactivation) - and they can assume one of three 
states: the closed state, the open state and the inactivated 
state.  This hypothetical system 8 is named to this date as 
“Hodgkin-Huxley kinetics”. 
Three “m” activation gates localized on the extra-
cellular side and one “h” inactivation gate on the intracel-
lular side can be considered to be lined up in series in the 
sarcolemmal membrane.
There are two gates for slow channels: the activa-
tion gate (“d”) and the inactivation gate (“f”) 9. 
Closed or resting state: 
The excitable (resting state) phase of the cell is 
electrical diastole, during which the “m” gate is closed 
and the “h” gate is open; the channel is closed but
excitable (“m” is closed and “h” is open). The Na+ channels 
are closed at negative potentials when the cell is in the rest-
ing state: Na+ does not normally enter resting cardiac cells.
Open state: 
The “m” gate is the activation gate. A channel is 
in the open state when the “m” gate opens briefl y, which 
the second, which is longer lasting, participates in phase 2 
- steady state or “window” current - as a slow Na+  channel 
type. It was proposed that an overlap between the activa-
tion (“m”) and inactivation (“h”) variables, which control 
the Na+ conductance, produces a window of slow current 
during phase 2 of AP, and it is possible that a slow compo-
nent of inward current exists 5(Figure 2)
Characteristics of the Na+ channel. This is a protein 
structure, formed by four modules that surround a cen-
tral pore. This channel has a main structure, called α and 
other surrounding accessory ones called β1 and β2. This
channel is very important in stimulus conduction and cell 
activation. Inherited mutations in SCN5A, the gene en-
coding the cardiac Na+ channel, provoke life-threatening 
cardiac arrhythmias, often by modifying these voltage-de-
pendent conformational changes. Nav1.5 consists of four 
domains (DI–DIV), each containing six transmembrane 
segments (S1–S6); S4 segments are positively charged 
and act as voltage sensors.
Sarcolemmal membrane
Table 2: Conduction velocity in the different regions of the 
heart
Region Velocity (mm/s)
Central region of the SA node 2 to 5
Peripheral region of the SA node 7 to 11
Internodal bundles 1000
Atrial ordinary muscle 400
AN region of AV node 100
N region of AV node 20
NH region of AV node 800
His, branches & Purkinje arborizations 4000
Ventricular ordinary muscle 400
Table 2 shows different conduction velocities of stimulation in diffe-
rent areas of the heart. The lowest conduction velocity is found in the 
central region of the SA node (2 to 5 mm/s) and the highest in the 
His-Purkinje system (4000 mm/s). AV: atrioventricular; SA: sinoatrial.
Figure 2: Representation of sarcolemmal membrane. the sodium 
channel structure and temporal correlation between monophasic 
action potential and the surface electrocardiogram.
The mean Na+ channel density is approximately 
200 channels per square micron 6.  Each channel initiates 
rapid depolarization and contributes to the control of AP 
duration (APD) by the steady state or “window” current.
In the heart, mediated rapid transmission of ex-
citation through the atria (P wave) and ventricle (QRS) 
and the delay of AV node enable synchronous ventricular 
ejection.
The cardiac Na+ channel isoform encodes hH1 and 
has been mapped to the short arm of chromosome 3 p21-
24 loci7. (Figure 3).
Figure 3: Representation of the sodium channel structure with the 
main central large α subunit and associated accessory β subunits. 
The  α subunit forms the core of the channel and is functional on 
its own. When the α subunit protein is expressed by a cell, it is 
able to form channels that conduct Na+ in a voltage-gated way, 
even if β subunits or other known modulating proteins are not ex-
pressed. When accessory proteins assemble with α subunits, the 
resulting complex can display altered voltage dependence and 
cellular localization.
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occurs when the membrane voltage reaches the threshold 
potential (-70 mV). This is a voltage-operated channel. At 
this time there are strong Na+ concentrations and electrical 
gradients that rapidly draw Na+ into the cell (phase 0 of 
the AP and P or QRS of ECG). This is the threshold for the 
stimuli to open the INa+ channel in response to specifi c 
substances interacting with specifi c receptors on the cell 
surface. The Na+ channel proteins change conformation 
to a conducting (“open”) state and allow up to 107 Na+ 
per second to enter each cell, moving the transmembrane 
potential toward ENa (- 65mV).
The “m” gate opens faster than the “h” gate closes, 
so for about 1 millisecond both gates are open simultane-
ously. (Figure 4)
Inactivated state: 
The channel is closed but not excitable, from which 
state the channel cannot open. The voltage-dependent “h” 
gate closes when the cell becomes positive on the inside. 
The inactivation of cardiac Na+ channel occurs exclusi-
vely through the open state10. 
Note especially that a comparatively small number 
of Na+ ions move into the cell during phase 0 of the AP. 
The concentration gradient for Na+ hardly changes as a 
result of the AP. 
The channel is inactivated and cannot respond to 
a stimulus until negative voltage is restored when it re-
sumes the rested or closed conformation. The surge of 
Na+ movement lasts only 1 ms after which the channel 
protein changes conformation from the “open” state to an
“inactivated”, that is, non-conducting state. The inactiva-
tion of a fast Na+ channel is produced by the intracellular 
loop connecting domains III and IV of a Na+ channel and 
can be thought of as forming a hinged lid. 
The critical residue (Phe 1489F) occludes the intra-
cellular mouth of the pore. A cluster of positively charged 
arginine and lysine residues in the S4 domain is thought to 
function as the voltage sensor (“m” gate) while the peptide 
loop connecting repeats S3 and S4 binds to the activated 
channel and occludes the intracellular mouth of the chan-
nel pore (“h” gate). 
The beginning of the inactivated state is partially 
responsible for phase 1 or rapid repolarization of the AP 
and the J point on the ECG. 
The remainder of the inactivation process is in 
phase 2 or “plateau” when a very small but important 
component of the Na+ channel is functioning, prolonging 
the refractory period. This phase corresponds to the ST 
segment on an ECG.
The inactivation usually takes place from the open 
state, but some channels may become inactivated before 
opening. The Na+ channel is voltage-dependent (a volt-
age-operated channel). The channel opens in response to
voltage - a process known as “activation”. Since the open-
ing and closing of the gates are voltage and time-depen-
dent, the permeability of the channel (P Na+) will be some 
fraction of the maximum possible permeability (PNa+, 
max) depending on membrane potential and the period 
that the membrane has been at that voltage. The Figure 5 
shows the closed and closed states of the sodium channel.
The predicted secondary structure of the cardiac 
Na+ channel and locations of mutations cause BrS, LQT3, 
PCCD, overlapping syndromes, AF, and atrial standstill. 
The channel consists of four putative transmembrane do-
mains (I–IV), with each domain containing six transmem-
brane segments S1–S6 BrS mutations green triangles, 
LQT3 red square, Lenègre disease blue circles, overlap-
ping BrS and Lenègre disease trapezoid pink and black 
triangle atrial standstill). Three “m” particles control ac-
tivation:
P
Na
 = m3 . h . P
Na,max
The sodium channel has two fundamental proper-
ties: ion conduction and gating.
Permeation/Conduction - the mechanism of the 
selective movement of Na+ ions across the pore in the cell 
membrane. This refers to all the pore properties of the 
channel, including how ions traverse the channels when 
they are open. It refers to the ability of a channel to con-
duct ions once it is open.       
Gating -  the mechanisms that open and close the 
sodium channel pore in response to a change in membrane 
potential. This describes the opening and closing of the 
sodium channel pore - how channels open and close. We 
can also say that it is the process whereby channels change 
Figure 4: Representation of the sodium (small violet circles) and
potassium (large blue circles) movements during action potential
(AP). The critical residue Phe-1489 (F) is shown occluding the 
intracellular mouth of the pore.
Figure 5: Representation of closed and open states of the sodium 
channel. The critical residue Phe 1489 F is shown occluding and 
opening the intracellular mouth of the pore. Concomitantly, the six 
membrane spanning subunits, labeled S1 through S6. The highly 
preserved S4 segment acts as the channel’s voltage sensor. The 
voltage sensitivity of this channel is due to positive amino acids 
located at every third position. When stimulated by a change in 
transmembrane voltage, this segment moves toward the extra-
cellular side of the cell membrane, allowing the channel to become
permeable to ions.
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their conformation in response to an external stimulus 
inactivation.   Na+ channel SCN5A gene mutations -apart 
from changing channel-gating characteristics- may be 
related to changes in channel protein traffi cking and ex-
pression. Regulation of ion channel protein expression 
depends on a fi ne-tuned balance among various processes: 
Gene transcription; RNA processing; protein synthesis; 
assembly and post-translational modifi cation; the trans-
port to the cell surface; the anchoring to the cytoskeleton 
and; regulation of endocytosis and controlled degradation 
of the protein.
The channel opens rapidly when the membrane 
potential reaches the threshold potential: About –60 mV 
to –70 mV in Purkinje fi bers. The Na+ ionic current in 
the channel is time-dependent and voltage-gated.  The 
selectivity of the channel for Na+ ions is at least 10 times 
greater than that of other monovalent cations, so the 
channel is highly selective for Na+ ions.  The Na+ channel 
does not normally conduct divalent cations.  A powerful 
blocker of Na+ entry into the channel is TTX (Tetrodo-
toxin).  Recently a spider cardiotoxin, designated jing-
zhaotoxin-III (JZTX-III), from the venom of the Chinese 
spider Chilobrachys jingzhao, showed higher selectivity 
on Voltage-Gated Na+  Channel (VGSCs) isoforms than 
other spider toxins affecting VGSCs, and the toxin hope-
fully represents an important ligand for discriminating 
cardiac VGSC subtypes. Unlike other spider peptides, 
it contains an uncommon endoproteolytic site (-X-Ser-) 
anterior to mature protein and the intervening regions of 
5 residues, which is the smallest in spider toxin cDNAs 
identifi ed to date. Under whole cell recording, JZTX-
III showed no effects on voltage-gated Na+  channels 
(VGSCs) or calcium channels in dorsal root ganglion 
neurons, whereas it signifi cantly inhibited tetrodotoxin-
resistant VGSCs with an IC (50) value of 0.38 microns 
in rat cardiac myocytes11. 
The α-subunit is a ≈2000-amino acid glycoprotein 
with four internally homologous domains labeled I to IV. 
The architecture is modular, with the proteins wrapped 
around a central pore 12. Each of these four domains con-
tains six transmembrane segments and resembles a single 
α-subunit of a voltage dependent K+ channel. 
The pore-lining (“P segment”) regions exhibit 
unusual conservation within a given channel family of 
like selectivity. The S6 segment of domain IV has been 
proposed to contain the receptor for local anesthetics, (li-
docaine and other “type I” antiarrhythmic drugs) which 
block the Na+   channel in a voltage-dependent manner 13. 
Acute, infl ammatory, and neuropathic pain can all 
be attenuated or abolished by local treatment with Na+ 
channel blockers such as lidocaine. According to the clas-
sic modulated receptor hypothesis, local anesthetics such 
as benzocaine and lidocaine bind preferentially to fast-
inactivated Na+ channels with higher affi nities. However, 
an alternative view suggests that activation of Na+ chan-
nels plays a crucial role in promoting high-affi nity local 
anesthetics binding and that fast inactivation per se is not a 
prerequisite for local anesthetics preferential binding. The 
Na+ channel activation pathway, including most, if not 
all, transient intermediate closed states and the fi nal open 
state, promotes high-affi nity local anesthetics binding 14. 
The Na+ cardiac channel has eight candidate PKA 
(Protein Kinase A) consensus phosphorylation sites in the 
II to IV linker of the form KRXXS*, RXXS*, or RXS*. 
When the channel is phosphorylated by PKA, the whole-
cell conductance increases. In contrast, PKC (Protein Ki-
nase C) activity reduces the conductance.
The α subunit of gene SCN5A is suffi cient to ex-
press a functional channel. Biochemical studies reveal the 
existence of two distinct β - subunits, β-1 and β-2, associ-
ated with the brain Na+ channel. 
β subunit coexpression increases the level of chan-
nel expression and alters voltage-dependent inactivation15. 
Na+ channel β subunits are multifunctional
molecules that participate in channel modulation and cell 
adhesion. Reversible, receptor-mediated changes in β1 ty-
rosine phosphorylation modulate its ability to recruit and 
associate with ankyrin.
β-1 has two components:
Tyrosine-phosphorylated β -1 (pY  β-1): Na+ chan-
nel complexes at intercalated disks of ventricular myo-
cytes are composed of Nav1.5 and pY β-1, and these com-
plexes are in close association with both N-cadherin and 
connexin-43 16;
1) Nonphosphorylated β-1 Na+ channels isolated 
from mammalian brain are composed of α, β-1, 
and β-2 subunits. The auxiliary β subunits do 
not form the ion conducting pore, yet play im-
portant roles in channel modulation and plasma 
membrane expression. β-1 and β-2 are trans-
membrane proteins with one extracellular V-
set immunoglobulin (Ig) protein domain. It has 
been shown recently that β-1 and β-2 interact 
with the extracellular matrix proteins tenascin-C 
and tenascin-R 17.
Na+ channel β subunits modulate channel kinetic 
properties and cell surface expression levels and function 
as cell adhesion molecules. β-1 and β-2 participate in ho-
mophilic cell adhesion resulting in ankyrin recruitment 
to cell contact sites. Ankyrin recruitment was observed 
in β-1 L182 (STOP), showing that residues Ile(166)-
Tyr(181) contain the major ankyrin recruiting activity 
of β-1. Ankyrin recruitment was abolished in β-1Y181E, 
suggesting that tyrosine phosphorylation of β-1 may in-
hibit β-1-ankyrin interactions. Ankyrin (G) and β-1 as-
sociate in rat brain membranes and in transfected cells 
expressing β-1 and ankyrin(G) in the absence of Na+ 
channel α subunits. β-1 subunits are recognized by anti-
phosphotyrosine antibodies following treatment of these 
cell lines with fi broblast growth factor β-1 and ankyrin(G) 
association is not detectable in cells following treatment 
with fi broblast growth factor. Ankyrin (G) and β-1Y181E 
do not associate even in the absence of fi broblast growth 
factor treatment. β -1 subunit-mediated cell adhesion 
and ankyrin recruitment may contribute to Na+ channel 
placement at nodes of Ranvier. The phosphorylation state 
of β-1Y181 may be a critical regulatory step in these
developmental processes18. 
Subunits may be differentially localized in the 
heart and thus interact with different cytoskeletal and sig-
naling proteins. 
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β-1 phosphorylation appears to regulate its lo-
calization to differential subcellular domains. It is a gua-
nidinium with high affi nity by an aromatic residue in the 
P region of domain I in position 373 in the hH1 sequence. 
Drugs that affect the Na+ channel
Other substances including local anesthetics and 
antiarrhythmic agents Class IA, IB and IC have TTX-like 
Na+ channel blocking properties19.
Class IA antiarrhythmics - Ajmaline, quinidine, 
procainamide and disopyramide phosphate - show inter-
mediate rapidity dissociation kinetics from the Na+ chan-
nel. These drugs have an intermediate kinetics greater than 
1 but less than 5 seconds. They reduce the Vmax (slow 
conduction) and prolong the AP duration (APD). Ajmaline 
differs only in the His-Purkinje system, causing a signifi -
cant shortening of the dome, plateau or phase 2 of AP.
Class I antiarrhythmic agents ajmaline and pro-
cainamide produce accentuation of ST elevation in pa-
tients with BrS, and have been shown to be effective in un-
masking BrS when concealed, transitory or intermittent.
Ajmaline is used through IV access, in a 10 mg 
dose each two minutes, until it reaches a 1-mg/kg dose20. 
A prolongation of > 30% of the QRS complex, and the
appearance of a typical type 1 Brugada pattern or prema-
ture ventricular contractions, are considered events that 
indicate the end of the test.
The responses could be varied:
1) In approximately 20 to 25% of the cases, a typi-
cal coved ST segment elevation at least 2 mm 
and 80 ms in duration from the J point in at 
least two right precordial leads or from V1 to 
V3, which means the test is positive for BrS. In 
a patient with ECG that suffered aborted SCD 
or syncope, without structural heart disease, if 
ajmaline causes this ECG pattern, ICD implan-
tation is indicated 21; 22; 23. Schmidt et al, report 
a 20-year-old patient suffering cardiopulmonary 
resuscitation due to VF. The authors diagnosed 
BrS after ruling out structural heart disease and 
a positive ajmaline test and implanted an ICD. 
It was found that one brother and one sister 
presented the beginning of RV dilatation and 
a fi brolipomatous area in the anterior wall seg-
ment of the RV compatible with “concealed” 
ARVC/D. The case report demonstrates the 
value of familiar examination of patients with 
an unclear ventricular arrhythmogenic event24. 
In order to examine a possible link between 
ARVD/C and BrS, systematic ajmaline testing 
with 1 mg/kg body weight intravenously, was 
performed by Peters et al 25 in 55 patients with 
ISFC/European Society of Cardiology criteria 26 
of ARVC/D. In nine patients’ ajmaline testing 
demonstrated type 1 BrP in the right precordial 
leads. The authors concluded that these obser-
vations with systematic ajmaline testing demon-
strate a defi nite link between ARVC/D and BrS. 
We disagree with these conclusions. We would 
argue that this result could also be interpreted 
to indicate that the ajmaline test is not specifi c 
for uncovering BrS.  A positive test is observed 
with ajmaline in cases of Chagasic myocardi-
tis, a parasitic cardiomyopathy, as well as with 
a wide variety of Na+  channel blockers in the 
acquired form of the syndrome 27.
2) There is a reference to the appearance of ex-
treme deviation of SÂQRS to the left in the 
frontal plane, concomitant with ST segment ele-
vation. The phenomenon probably refl ects a left 
anterior fascicular block due to the predominant 
effect of the drug on the His-Purkinje system28. 
The test may differentiate the cases of ARVD/C, 
where the use of class IA antiarrhythmic agents, 
ajmaline and procainamide (ajmaline 1 mg/kg), 
procainamide (10 mg/kg) or class IC (fl ecainide 
2 mg/kg) does not cause ST segment elevation. 
In some patients previously classifi ed as having 
IVF, the test of ajmaline or procainamide un-
masks the typical ECG BrP, suggesting that this 
incidence could be higher than what was sus-
pected previously29;
3) In the IV test of ajmaline in BrS, concomitantly 
with ST segment elevation in the right precor-
dial leads, a delay is observed in the zero phase 
(upstroke) of the monophasic AP (MAPs) exclu-
sively or more pronounced in the RVOT30; 
4) Symptomatic VT (rare, less than 1.5%)
5) Monomorphic VT has been described after in-
jection of ajmaline in BrS patients31;
6) In patients carriers of BrS, the area estimated 
of ST segment elevation, using body surface 
potential mapping, in the presence of posterior 
potentials and certainty at PES, constitutes a va-
luable noninvasive marker in risk stratifi cation; 
and when ajmaline is used, this estimated area 
of ST segment elevation increases even more;
7) Using body surface potential mapping, it was 
observed that in the left precordial leads, the pa-
tients with BrS showed the mirror or reciprocal 
image of the shifts occurred in the right precor-
dial leads, and these shifts are increased when 
ajmaline is used;
8) ST segment elevation has rarely been observed 
from V1 to V2 without arrhythmias, which may 
mean silent ischemia not detected previously, 
transmural dispersion of conduction and re-
fractoriness in the RV outfl ow tract or HR-de-
pendent Na+ channel block;
9) In patients with normal baseline ECG, approxi-
mately 2% of the cases, the test results positive. 
The test is indicated in all patients that suffered 
aborted SCD or unexplained syndrome, with-
out structural heart disease, in whom the ECG 
would not spontaneously show the typical ECG 
Brugada pattern. Also, in the relatives of the
affected patients. The test with this drug in BrS 
is considered a very useful tool.
Class IB antiarrhythmic agents - Mexiletine, phe-
nytoin, tocainide, lidocaine, and apridine - show rapid dis-
sociation kinetics from the Na+ channel (<500 ms). These 
drugs do not reduce Vmax .and shorten APD32.  The QRS 
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duration and JT interval are not prolonged with these 
drugs, however mexiletine has a rate-dependent blocking 
effect on Na+ channel that might be intensifi ed under hy-
perkalemia 33.  They have little effect on the APD and con-
duction in normal tissues but would depress the conduc-
tion of closely coupled premature ventricular contractions 
(PVCs) as well as partially depressed cells. These drugs 
have dissociation time constants of less than 1 second. 
Drugs with fast-blocking kinetics of interaction 
with the Na+  channel may have a selective effect on con-
duction during tachycardia.  Mexiletine decreases QTc in-
terval as well as dispersion of repolarization in LQT3 syn-
drome but has no effect on BrS34. Mexiletine is used for 
ventricular arrhythmias but is also found to be effective 
for paramyotonia congenita, potassium-aggravated myo-
tonia, LQT3 variant of congenital LQTS and neuropathic 
pain. Effi cacy of mexiletine is primarily due to the open-
channel block of persistent late Na+ currents, which may 
arise during various pathological conditions35. Mexiletine, 
is most effective in abbreviating QT interval in LQT3, but 
effectively reduces transmural dispersion of repolariza-
tion (TDR) and prevents the development of Torsade de 
Pointes (TdP) in all classical 3 models: LQTS, suggesting 
its potential as an adjunctive therapy in LQT1 and LQT236. 
Chang et al37 described a novel, spontaneous LQT3 
mutation identifi ed in the transmembrane segment 6 of 
domain IV of the Na(v)1.5 cardiac Na+  channel, with a 
G-->A substitution at codon 1763, which changed a valine 
(GTG) to a methionine (ATG). The patient was a newborn 
with fetal bradycardia, 2:1 atrioventricular block and VT 
soon after birth. The 2:1 atrioventricular block improved 
to 1:1 conduction only after intravenous lidocaine infu-
sion or a high dose of mexiletine, which also controlled 
the VT. The Na(v)1.5/V1763M channel dysfunction and 
possible neighboring mutants contribute to a persistent in-
ward current due to altered inactivation kinetics and clini-
cally congenital LQTS with perinatal onset of arrhythmias 
that responded to lidocaine and mexiletine.  
 Class IC antiarrhythmics - Flecainide, pilsicainide, 
propafenone, encainide, moricizine and lorcainide - show 
dissociation kinetics in the Na+ channel (10 to 20 seconds). 
These drugs reduce Vmax and can minimally increase the 
refractoriness index, which is based on the ratio between 
the relative refractory period and the APD. 
Flecainide acetate: Class IC drugs produce
markedly slower conduction but have little effect on the 
APD. Flecainide is an antiarrhythmic agent that belongs 
to the class IC of the Vaughan Williams classifi cation, 
which causes a potent inhibition on the Na+  channel by 
possessing a slow binding and dissociation kinetics with 
this channel (10 seconds to 30 seconds). The data indicate 
that fl ecainide rapidly gains access to its binding site when 
the channel is open and inhibits Na+ channel by a pore
blocking mechanism. Closing of either the activation or 
the inactivation gate traps fl ecainide within the pore re-
sulting in the slow recovery of the drug-modifi ed channels 
at hyperpolarized voltages38. Other channels affected by 
the drug are the Ito1 channel in therapeutic concentrations 
and rate-independent; the ICa
2+ channel in high concen-
trations and the fast rectifi er potassium channel IKr in a 
voltage-dependent fashion. 
A low dose of oral fl ecainide shortens the QTc in-
terval and normalizes the T wave repolarization pattern in 
patients with the LQT3 variant with the DeltaKPQ muta-
tion of SCN5A. The DeltaKPQ mutation presents repeti-
tive reopening of Na+ channel and a slow and prolonged 
cation-entrance current in phase 239. Thus, fl ecainide in 
low doses is a promising therapeutic agent for patients 
with LQTS with the DeltaKPQ mutation of SCN5A in the 
Na+ channel. It was verifi ed that only fl ecainide (and not 
lidocaine) corrects the LQT3 phenotype in DG mutation 
carriers.
These results prove that this mutation confers a 
unique pharmacological response in the expression of the 
channels, and it is known that the DG channels block by 
fl ecainide acts on the C-terminal of the α subunit of the 
Na+ channel by a fl ecainide/channel interaction. Associa-
tion of oral fl ecainide with ICD could be effective in the 
LQT3 variant. Harkel et al40 presented a case in which 
LQTS induced severe prenatal and neonatal arrhythmias. 
LQT3 was diagnosed (mutation R1623Q).
Short-acting β-blockers were ineffective as well as 
sotalol and mexiletine in preventing recurrent ventricular 
arrhythmias. An ICD was implanted at the age of 7 months 
(weight and length of the infant at implantation 6 kg and 
60 cm respectively). Flecainide was prescribed in addition 
to the ICD implantation. After an appropriate shock the 
fl ecainide plasma levels were shown to be sub-therapeutic. 
Readjustment of the fl ecainide dose resulted in adequate 
plasma levels. No further shocks occurred during a further 
17 months’ follow-up period. The combination of an ac-
tive can with a subcutaneous patch proved feasible, and 
lifesaving shocks occurred at 7 months after implantation.
Clinical management of LQT-3 and diagnosis of 
BrS with the local anesthetic fl ecainide has proven prom-
ising. Channels associated with LQT-3 (D1790G) and 
BrS (Y1795H) both show more sensitivity to fl ecainide 
than wild-type (WT) channels, while lidocaine sensitiv-
ity is unchanged. One plausible explanation for differ-
ential drug sensitivity is that mutant channels may allow 
more access to a receptor site compared with wild-type 
through altered protein allosteric changes during action 
potential. The high affi nity binding site for local anes-
thetic block has been identifi ed in the pore region of the 
channel. This region is not water accessible during the 
closed state, thus requiring channel opening for charged 
drug (fl ecainide and mexiletine) access and block.
Channel mutations which disrupt inactivation bio-
physics lead to increased drug binding by altering the 
time the binding site is accessible during an AP. Neutral 
drugs (lidocaine) which are not dependent on channel 
opening for binding site access will not be sensitive to 
mutations that alter channel inactivation properties. In-
terestingly another LQT-3 mutant (Y1795C) shows no 
change in fl ecainide sensitivity, suggesting that although 
drug effects of SCN5A mutations cross disease boundar-
ies, clinical management with fl ecainide will be benefi -
cial to patients in a mutation-specifi c manner41.
Flecainide has a predominant negative dromotrop-
ic effect in high rates and more intense than class IA drugs, 
which may involve ventricular performance in patients 
with ejection fraction previously affected. 
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These agents have the slowest dissociation rate: 
greater than 12 seconds. QRS widening may be ob-
served at therapeutic levels of drug concentration. The 
incidence of proarrhythmic response appears highest 
with this class of drugs because the half time of re-
covery is greater. It shortens AP in Purkinje fi bers (prob-
ably by delayed gating Na+ channel block) and on the 
contrary, it prolongs AP in the muscle fi bers of ventri-
cles and atria (possibly by block of delayed rectifi er cur-
rents)42. In the latter, the drug prolongs AP signifi cantly 
at high heart rates; unlike quinidine that prolongs AP at 
slow rates43. Flecainide and quinidine increase AP du-
ration (APD) in the human atrial tissue; however, with 
an opposite dependence on HR. The effect of the drug 
increasing APD and refractoriness at high rates is very 
useful in AF reversion with a high rate of ventricular 
response. The mechanism by which it acts reversing AF 
is by prolonging that of the atria. 
Class IA and IC antiarrhythmic drugs increase ST-
segment elevation and predilection for PVT and VF in 
BrS, whereas these agents shorten the repolarization and 
QT(c) interval. Arrhythmias are suppressed by mexiletine, 
for the late persistent Na+ channel 44   and thus may be 
benefi cial in LQT3 syndrome.
An area of possible crucial application of the mo-
lecular genetic of cardiac ion channels, is the so-called 
drug-induced TdP and acquired LQTS. This condition is 
defi ned as an abnormal response to the administration of 
a variety of drugs which, in susceptible subjects, may in-
duce an excessive QT interval prolongation and possibly 
lead to the onset of life-threatening ventricular tachyar-
rhythmias (drug-induced TdP). The “proof of concept” 
that sub-clinical variants of the inherited LQTS may play 
a causative role has been recently brought to light. How-
ever, large population-based studies are still needed in 
order to quantify the epidemiological relevance of such 
fi ndings. The future developments in this area of research 
will lead to the availability of pre-prescription genotyping 
for the identifi cation of the susceptible subjects and to the 
development of safer drugs45. 
Sodium channelopathies: the different pheno-
types of the SCN5A mutation46
Several families of mutations have been identifi ed 
in SCN5A, the gene that encodes the human cardiac Na+ 
channel α-subunit (hH1). Inherited mutations in SCN5A, 
the gene encoding the pore-forming subunit of the cardiac 
Na+ channel, have been associated with distinct cardiac 
rhythm syndromes.
Mutations in the cardiac Na+ channel can lead to 
several clinical arrhythmogenic disorders with SCD and 
epileptic tendency46.
Mutations in SCN5A lead to a broad spectrum of 
phenotypes, however the SCN5A gene is not commonly 
involved in the pathogenesis of BrS and associated dis-
orders 47. Studies have revealed signifi cant overlap be-
tween aberrant rhythm phenotypes, and single mutations 
have been identifi ed that evoke multiple rhythm disorders 
with common gating lesions. These new insights enhance 
understanding of the structure-function relationships of 
voltage-gated Na+ channels, and also highlight the com-
plexities involved in linking single mutations, ion-channel 
behavior, and cardiac rhythm. 
The biophysical characterization of the Na+ chan-
nelopathies associated with different phenotypes and 
the genotype-phenotype correlation studies brought to 
the attention of the scientifi c community a plethora of 
mechanisms by which even a single amino acid substi-
tution may remarkably affect cardiac rhythm. The evi-
dence of patients harboring an SCN5A mutation and 
overlapping clinical presentations creates a need for a 
revision of the traditional classifi cation of mentioned 
channelopathies48. 
It is appropriate to consider the “Na+ channel syn-
drome” as a unique clinical entity that may manifest itself 
with a spectrum of possible phenotypes49.
The known phenotypes are:
1) Congenital long-QT syndrome variant 3 (LQT3) 
associated with an increased incidence of TdP 
and SCD. The mutation in SCN5A causing 
LQTS leads to gain of function with delayed in-
activation of the channel resulting in prolonged 
AP and ST segment and late onset T wave on 
ECG. In LQTS, ion channel mutations cause a 
preferential prolongation of the M cell AP that 
contributes to the development of long QT in-
tervals, a large transmural dispersion of repo-
larization, which provides the substrate for the 
development of TdP. An early afterdepolariza-
tion-induced triggered beat is thought to provide 
the PVC that precipitates TdP49. Mexiletine is ef-
fective in reducing dispersion of repolarization 
and preventing TdP in LQT2 and LQT3 models50. 
2) Brugada syndrome: It is characterized by ECG 
fi ndings of J point and ST elevation ≥ 2 mm in 
the right precordial leads followed by negative 
T wave called type 1 Brugada pattern (BrP). 
Mutations in the SCN5A gene known to cause 
BrS in ≈ 20% of cases are thought to be loss 
of function of the Na+ channel. It is the basis 
of the BrS clinical phenotype51. When related 
to the SCN5A gene, the loss of function of car-
diac Na+ channels, either by reducing expression
levels or by increasing its inactivation kinetics, is 
the main pathological origin of BrS. ECG fi nd-
ings are not always present and may be triggered 
by Na+ channel antagonists. Mutations in other 
genes have not been identifi ed, and it is not known 
if the effi cacy of drug testing or the malignancy 
of arrhythmias correlates to the gene defect. A 
study identifi es an expression-defective BrS mu-
tation in SCN5A with pharmacological rescue. 
Valdivia et al. identifi ed an expression-defective 
BrS mutation in SCN5A with pharmacological 
rescue. The profoundly decreased Na+ current as-
sociated with G1743R suggests a molecular ba-
sis for the delayed His-Purkinje conduction and 
elevated high defi brillation thresholds observed 
in the proband. Whether the mutant channel may 
be rescued in vivo by mexiletine and normalize 
the patient’s electrophysiological parameters re-
mains to be tested52. (Figure 6)
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 It is appropriate to consider the “Na+ channel 
syndrome” (mutations in Na+ channel α-subunit 
gene SCN5A) as a unique clinical entity that 
may manifest itself with a broad spectrum of 
possible phenotypes. Mutations in the Na+ chan-
nel gene SCN5A are found in ≈20% of cases 
while mutations in other genes collectively ac-
count for <5%. Ion channel dysfunction, in par-
ticular in the cardiac Na+ channel, may not be a 
prerequisite for BrS. 
3) Some Sudden Infant Death Syndrome cases: 
BrS has been linked to the sudden infant death 
syndrome (SIDS) by showing that the ECG and 
mutations are the same as in BrS. Approximately 
2% of prospective, population-based cohort of 
SIDS cases had an identifi able SCN5A channel 
defect, suggesting that mutations in cardiac ion 
channels may provide a lethal arrhythmogenic 
substrate in some infants at risk for SIDS  53; 54; 
4) Some Sudden Unexplained Nocturnal Death 
Syndrome (SUNDS) 55;
5) Idiopathic ventricular fi brillation without typi-
cal ECG fi ndings of BrS 56
6) Progressive cardiac conduction disease or Le-
nègre disease conduction block. PCCD is de-
fi ned by isolated prolongation of the conduc-
tion parameter in the His-Purkinje conduction 
system but no ST-segment elevation or QT 
prolongation. It is also associated with a risk 
of complete atrioventricular block and Stoke-
Adams syncope. The pathophysiology sequence 
of PCCD results from a loss-of-function of the 
cardiac Na+ channel57;
7) Mixed forms:  LQT3 and BrS58; overlapping 
clinical features of BrS and cardiac conduction 
disease. The same mutation in the SCN5A gene 
can lead either to BrS or to an isolated cardiac 
conduction defect59. Weiss et al, described a 
large multigenerational family with an autoso-
mal dominant form of BrS associated with pro-
gressive conduction disease, a low sensitivity 
to procainamide testing, and a relatively good 
prognosis in a single large pedigree, age- and 
sex-dependent. Linkage to a locus on chromo-
some 3p22-25 distinct from SCN5A is identi-
fi ed, confi rming genetic heterogeneity of the 
disorder. The low incidence of SCD in this 
family and the relative resistance to Na+ chan-
nel–blocking agents raise the possibility that the 
effi cacy of diagnostic and therapeutic interven-
tions may be gene-dependent60. It is named BrS 
type 2.
 LQT3, BrS and conduction system disease 
linked to a single Na+ channel mutation was re-
ported by Grant et al. The authors have iden-
tifi ed a four-generation family, including 17 
gene carriers with LQT3, BrS, and conduction 
system disease with deletion of lysine 1500
(DeltaK1500) within the linker. The late com-
ponent of Na+ current was increased in the Del-
taK1500 mutant channel. These changes can 
account for the complex phenotype in this kin-
dred and point to an important role of the III/IV 
linker in channel activation61; 
 Congenital long QT syndrome with 2/1 atrio-
ventricular block62; 
 Rossenbacker et al described a novel pore muta-
tion, R376H, in the fi rst pore segment of SC-
N5A that variably causes BrS and/or conduction 
disease in a single family. The phenotype in the 
family members is highly variable and ranged 
from non-inducible and inducible asymptomatic 
carriers of the mutations to isolated conduction 
disease and to symptomatic BrS. Recognition of 
factors modifying the clinical presentation may 
be important for clinical decision making63. 
 A novel human Na+ channel mutation, (SCN5A) 
E161K was identifi ed by Smits et al.,  in indi-
viduals of two non-related families with symp-
toms of bradycardia, sinus node dysfunction, 
generalized conduction disease and BrS, or 
combinations thereof. A loss of Na+ channel 
function is not only associated with BrS and 
conduction disease, but may also cause sinus 
node dysfunction in carriers of this mutation64; 
8) Congenital epilepsy65;
Figure 6: Representation of  numerous phenotypes  consequence 
of SCN5A gene mutations: Early repolarization syndrome (ERS); 
Brugada syndrome (BrS); Congenital long QT syndome variant 
3 (LQT3);  Progressive Cardiac Conduction Disease (PCCD) or 
Lenègre disease; Sick Sinus Syndrome (SSS); Sudden Unex-
plained Nocturnal Death Syndrome (SUNDS);  Multifocal Ectopic 
Purkinje-related Premature Contractions (MEPPC); Sudden Infant 
Death Syndrome (SIDS); Overlapping syndromes; Dilated Cardio-
myopathy (DCM); and Familial Atrial Fibrillation (FAF).
Figure 7: Shows the point of mutation in the diverses phenotypes: 
green triangle Brugada syndrome; yellow triange overlappying 
BrS, LQT3 or Lenegre disease; red square: LQT3; blue circle 
PCCD or Lenègre disease; Purple diamond shape BrS/PCCD; 
black triangle: SSS/SND or atrial standstill.
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In BrS the site of the mutations is different than 
that of chromosome 3-linked congenital LQT3 and does 
not result in a prolonged QT interval.  LQT3 and BrS due 
to the SCN5A gene seem to be electrophysiological mir-
ror images with LQTS due to gain of function and BrS 
due to loss of function. Coexistence of these syndromes 
is seemingly paradoxical; LQT3 is associated with gain in 
Na+ channel function, and BrS with reduced function. The 
1795insD mutation can cause both LQT3 and BrS through 
interaction with the heterogeneous myocardium in a rate-
dependent manner. The results highlight the complex-
ity and multiplicity of genotype-phenotype relationships,
and the usefulness of computational approaches in estab-
lishing a mechanistic link between genetic defects and func-
tional abnormalities66. The substitution (D1790G) causes 
LQTS and the insertion (D1795) induces both LQT3 and 
BrS in carrier patients67. For both D1790G and insD1795, 
there is a persistent inward Na+ current of about 6% at - 30 
mV. In addition, there is a 62% reduction of channel expres-
sion for the insD1795. hH1/ins D1795 and hH1/D1790G 
mutant channels were expressed in the tsA201 human cell 
line and it was functionally characterized using the patch 
clamp technique in whole-cell preparation. 
D1790G (DG), an LQT3 mutation of the C-termi-
nal region of the sodium channel α-subunit, alters steady-
state inactivation of expressed channels but does not pro-
mote sustained sodium channel activity68.
The C-terminus of Na(v)1.8 contributes to regula-
tion of channel density at the cell surface, modulates channel
gating, and regulates the generation of sustained current69. 
Other sodium channel mutations observed in BrS 
and LQT3 include the R1512W mutation (producing a 
slowing of both inactivation and recovery from inactiva-
tion) and the R4132G mutation, respectively. The E1784K 
mutation found in LQT3 showed persistent inward Na+ 
current, a hyperpolarized shift of the steady-state inactiva-
tion, and a faster recovery from inactivation70.
Paradoxically, an inherited C-terminal SCN5A 
mutation causes affected individuals to manifest ECG 
features of both syndromes: QT-interval prolongation 
(LQT3) at slow heart rates and distinctive ST-segment
elevations (BrS) with exercise. The insertion of the amino 
acid 1795insD has opposite effects on two distinct kinetic 
components of Na+ channel gating (fast and slow inactiva-
tion) that render unique, simultaneous effects on cardiac 
excitability. The mutation disrupts fast inactivation, caus-
ing sustained Na+ current throughout the AP plateau and 
prolonging cardiac repolarization at slow heart rates 71. 
At the same time, 1795insD augments slow inactivation, 
delaying recovery of Na+ channel availability between 
stimuli and reducing the Na+ current at rapid heart rates. 
Research has revealed a novel molecular mecha-
nism for BrS and identifi ed a new dual mechanism
whereby single SCN5A mutations may evoke multiple 
cardiac arrhythmia syndromes by infl uencing diverse 
components of the Na+ channel gating function72. 
A calcium sensor Calmodulin (CaM), a ubiqui-
tous Ca2+ sensing protein, binds to the carboxy-terminal 
‘IQ’ domain of the human cardiac Na+ channel (hH1) in a 
Ca2+ dependent manner. This binding interaction signifi -
cantly enhances slow inactivation-a channel-gating pro-
cess linked to life-threatening idiopathic ventricular ar-
rhythmias. A mutation (A1924T) in the IQ domain altered 
hH1 function in a manner characteristic of the Brugada 
arrhythmia disease, but at the same time inhibited slow 
inactivation induced by Ca2+/CaM, yielding a clinically 
benign phenotype73. 
The cardiac ryanodine receptor (RyR) is the sar-
coplasmic reticulum (SR) Ca-release channel that is in-
volved in the myocyte excitation-contraction, coupling 
process and certain cardiac arrhythmias, and even con-
tributes to pacemaker activity in the heart. The RyR is also 
the center of a massive macromolecular complex, which 
includes numerous regulatory proteins, which can modu-
late RyR function. This complex includes proteins that 
interact with the cytoplasmic part of the RyR directly or 
indirectly: calmodulin (CaM), FK-506-binding proteins, 
protein kinase A, Ca-CaM-dependent protein kinase, 
phosphatases 1 and 2A, mAKAP, spinophilin, PR130, sor-
cin, triadin, junctin, calsequestrin and Homer. Information 
is evolving in terms of understanding both the physical/
molecular nature of the protein-protein interactions be-
tween RyR and these other proteins74. The use of class 1C 
antiarrhythmic drugs fl ecainide and pilsicainide causes an 
increase in ST segment elevation in right precordial leads 
and the inferior wall, resembling inferior ischemia75. 
Na+ channel blockade by antiarrhythmic drugs im-
proves the QT interval prolongation in LQT3 but wors-
ens BrS ST-segment elevation. Although Na+ channel 
blockade has been proposed as a treatment for LQT3, fl e-
cainide also evokes “Brugada-like” ST-segment elevation 
in LQT3 patients. Low-dose, oral fl ecainide consistently 
shortened the QTc interval and normalized the repolariza-
tion T-wave pattern in fi ve LQT3 patients with SCN5A: 
DeltaKPQ mutation. DeltaKPQ is associated with repeti-
tive reopening of the Na+ channel and prolonged inward 
current. This dominant inward current is manifested on the 
ECG as QT interval prolongation. This preliminary study 
indicates that low-dose fl ecainide is a promising therapeu-
tic agent for LQTS patients with the SCN5A: DeltaKPQ 
Na+ channel mutation.
Some researchers have wondered if LQT3 syn-
drome and BrS are two aspects of the same disease. It is 
believed that both result in opposite molecular effects: 
BrS mutations cause reduced Na+ current, while LQT3 
mutations are associated with a gain of function. The ef-
fects of class I antiarrhythmic drugs have been used to 
differentiate these diseases. Intravenous fl ecainide is used 
as a test to unmask the electrocardiographic phenotype of 
BrS. On the other hand, on the basis of experimental and 
clinical studies, the possibility that some drugs act as a 
gene-specifi c therapy in this disorder by contrasting the 
effect of mutations in LQT3 has been explored. Recent
evidence shows that phenotypic overlap may exist between 
BrS and LQT3. One large family with a SCN5A mutation 
and a “mixed” ECG pattern (prolonged QT interval and 
ST-segment elevation) has been reported. Moreover, re-
cent data has shown that the fl ecainide test may elicit ST-
segment elevation in some LQT3 patients. The presence 
of “intermediate” phenotypes highlights a remarkable
heterogeneity suggesting that clinical features may depend 
upon a single mutation. Only an in-depth understanding 
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of the genotype-phenotype correlation will allow both 
the determination of an individual patient’s risk and the
development of guidelines for clinical management.
Defects of the SCN5A gene encoding the cardiac 
sodium channel α-subunit are associated with both the 
LQT3 subtype of long-QT syndrome and BrS. 
One previously described SCN5A mutation 
(1795insD) in the C terminus results in a clinical phe-
notype combining QT prolongation and ST segment
elevation, indicating a close interrelationship between the 
two disorders. Rivolta et al76 provide additional evidence 
that these two disorders are closely related. They report 
the analysis of two novel mutations on the same codon, 
Y1795C (LQT3) and Y1795H (BS), expressed in HEK 
293 cells and characterized using whole-cell patch clamp 
procedures. The authors fi nd marked and opposite effects 
on channel gating consistent with the activity associated 
with the cellular basis of each clinical disorder. Y1795H 
speeds and Y1795C slows the onset of inactivation. The 
Y1795H, but not the Y1795C mutation causes a marked 
negative shift in the voltage dependence of inactivation, 
and neither mutation affects the kinetics of the recovery 
from inactivation. Both mutations increase the expres-
sion of sustained sodium channel activity compared with 
wild type (WT) channels, although this effect is most pro-
nounced for the Y1795C mutation, and both mutations 
promote entrance into an intermediate or a slowly devel-
oping inactivated state. The way in which the C-terminal 
tail of the cardiac sodium channel controls channel gating 
illustrates how subtle changes in channel biophysics can 
have signifi cant and distinct effects in human disease, and, 
additionally, provides further evidence of the close inter-
relationship between BrS and LQT3 at the molecular level.
Bezzina et al77 have screened the SCN5A gene 
in a large 8-generation kindred characterized by a high 
incidence of nocturnal sudden death, and QT-interval 
prolongation and the “Brugada ECG” occurring in the 
same subjects. An insertion of 3 nucleotides (TGA) at 
position 5537, predicted to cause an insertion of aspartic 
acid (1795insD) in the C-terminal domain of the protein, 
was linked to the phenotype identifi ed in all ECG trac-
ings of affected family members. ECGs were obtained 
from 79 adults with a defi ned genetic status (carriers, n 
= 43; non carriers, n = 36). In affected individuals, PR 
intervals, QRS durations and QT intervals were prolonged 
(P < 0.0001 for all parameters). ST segment elevation in 
the right precordial leads is present as well (P < 0.0001). 
Twenty-fi ve family members died suddenly, 16 of them 
during the night.
Expression of wild-type and mutant sodium chan-
nels in Xenopus oocytes revealed that the 1795insD muta-
tion gives rise to a 7.3 mV negative shift of the steady-
state inactivation curve and an 8.1 mV positive shift of the 
steady-state activation curve. 
The functional consequence of both shifts is likely 
to be a reduced Na+ current during the upstroke of the AP. 
LQT3 and BrS are allelic disorders but may also share a 
common genotype. The balance between therapeutic and 
adverse effects from sodium channel blockade by antiar-
rhythmic compounds may be shifted by subtle alterations 
in sodium channel function. 
Sodium channel blockers amplify existing INa+ 
and possibly other ion channel defects, with a potency in-
versely proportional to the rate of dissociation of the drug 
from the Na+ channel, thus causing a prominent elevation 
of the ST segment (observed in the V2 or V3 leads under 
baseline conditions, it was greater in the Brugada patients 
than in control patients) and, in some cases, prolonged 
QRS duration has occurred in patients with BrS.
A patient with idiopathic VF and a normal ECG 
or suspected intermittent variation should be given
ajmaline, procainamide or fl ecainide. A 12-lead ECG 
must be done previous to and after administering the drug. 
In 0.5% of cases VF might be provoked. Positive cases 
are those where a typical electrocardiographic pattern is 
evident. In these cases the patient should undergo elec-
trophysiological study in order to measure H-V. The phar-
macological test for family members is indicated. Asymp-
tomatic carriers of BrS should be periodically submitted to 
24-hour Holter monitoring78.
Animal models have shown that class I antiar-
rhythmic drugs increase the sodium channel number as 
much as three-fold 79. This is one explanation why class I 
drugs could increase late incidence of SCD after myocar-
dial infarction8-81.
The expression of sodium channels is dynamic and 
fl uctuates over relatively brief time intervals depending on 
an individual’s exposure to these drugs.
It seems that this channel is not directly in-
fl uenced by neurotransmitter, β-adrenergic, α-adrenergic 
or muscarinic cholinergic drugs. β-blockers may decrease 
the sodium channel density, leaving cell membranes less 
excitable and therefore less prone to VF and diminishing 
post-infarction risk of SCD.
Low pH decreases both the association and dis-
sociation rates of drugs with the sodium channel. Only 
when low pH is combined with membrane depolarization 
is there a net increase in blockage produced by local anes-
thetic-class drugs.
Tetrodotoxin and local anesthetics block the two 
types of Na+ channels, thereby diminishing the rate of rise 
of phase 0 and shortening the APD13.
Free polyunsaturated fatty acids (PUFAs)
inhibit sarcolemmal sodium channels and reduce cytosolic 
Ca2+82. PUFAs do not appear to upregulate the Na+ chan-
nel number. Polyunsaturated fatty acids can prevent fatal 
cardiac arrhythmias because they increase the threshold 
potential to 50% and decrease the Relative Refractory Pe-
riod (RRP) of AP83 (In this period, a strong stimulus can 
elicit a response, but the timing will be out of sync with 
the rest of the heart and arrhythmias can occur).
The cardiac sodium channel protein is a multi-
meric complex consisting of an α and an auxiliary protein 
β-subunit: β-1 and β-2, with molecular weights of 23 and 
21 kDa respectively.  The functional role of the β-1 sub-
unit in the heart is uncertain and there is no evidence of the 
expression of β-2 in myocytes.
In BrS, cardiac sodium channel dysfunction is ag-
gravated by the β-1 subunit84. These authors characterize 
the altered effects of a human β-1-subunit (h β (1)) on the 
heterologously expressed hH1 mutation (T1620M) pre-
viously associated with IVF. It is suggested that coexpres-
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sion of h β (1) exposes a more severe functional defect 
that results in a greater overlap in the relationship between 
channel inactivation and activation (window current) 
in T1620M, which is proposed to be a potential patho-
physiological mechanism of IVF in vivo. One possible 
explanation for this fi nding is an altered α-/β (1)-subunit 
association in the mutation.
The biophysical properties of the SCN5A mutation 
T1620M associated with BrS were examined for defects in 
intermediate inactivation (I:(M)), a gating process in Na+ 
channels with kinetic features intermediate between fast 
and slow inactivation85. Cultured mammalian cells express-
ing T1620M Na+ channels in the presence of the human β-1 
subunit exhibit enhanced intermediate inactivation at both 
22°C and 32°C compared with wild-type recombinant hu-
man heart Na+ channels (WT-hH1). BrS is caused, in part, 
by functionally reduced sodium current in the myocardium 
due to an increased proportion of sodium channels that en-
ter the I:(M) state. This phenomenon may contribute signifi -
cantly to arrhythmogenesis in patients with BrS.
Postema et al. ask: Do we really understand what’s 
going on? Long-QT syndrome, BrS, and conduction
disease may be caused by mutations in the cardiac sodium 
channel gene SCN5A, and from the ECG one can already 
presume either a gain- or a loss-of-function defect. The 
authors described a family harboring 2 SCN5A mutations: 
the DeltaKPQ mutation, the “classical” gain-of-function 
mutation associated with LQT3, and the I1660V muta-
tion, a loss-of-function mutation associated with BrS.
However, they were surprised by the result of genetic 
testing in this family. One son who carried the DeltaKPQ 
mutation but not the I1660V mutation did not show the 
expected Long-QT phenotype but, unexpectedly, showed 
a conduction disease/Brugada phenotype86. 
The role of mitochondria in Brugada Syndrome 
Pyridine nucleotides regulate the cardiac Na+ cur-
rent (INa) through generation of reactive oxygen species. 
Liu et al87 investigated the source of reactive oxygen spe-
cies induced by elevated NADH. Nicotinamide adenine 
dinucleotide, abbreviated NAD+, is a coenzyme found in 
all living cells. The compound is a dinucleotide, since it 
consists of two nucleotides joined through their phosphate 
groups, with one nucleotide containing an adenine base 
and the other containing nicotinamide.
In metabolism, NAD+ is involved in redox re-
actions, carrying electrons from one reaction to another. 
The coenzyme is, therefore, found in two forms in cells: 
NAD+ is an oxidizing agent – it accepts electrons from 
other molecules and becomes reduced. This reaction forms 
NADH, which can then be used as a reducing agent to 
donate electrons. These electron transfer reactions are the 
main function of NAD+. However, it is also used in other 
cellular processes, the most notable one being a substrate 
of enzymes that add or remove chemical groups from pro-
teins, in posttranslational modifi cations. Because of the 
importance of these functions, the enzymes involved in 
NAD+ metabolism are targets for drug discovery.
In human embryonic kidney (HEK) cells stably 
expressing the cardiac Na+ channel, the decrease of INa in-
duced by cytosolic NADH application (100 mumol/L) was 
reversed by mitoTEMPO, rotenone, malonate, DIDS (4’-di-
isothiocyanatostilbene-2,2’-disulfonic acid), PK11195, and 
4’-chlorodiazepam, a specifi c scavenger of mitochondrial 
superoxide and inhibitors of the mitochondrial complex I, 
complex II, voltage-dependent anion channels, and benzo-
diazepine receptor, respectively. Anti-mycin A, a complex 
III inhibitor known to generate reactive oxygen species, 
decreased INa. This effect was blocked by NAD (+), for-
skolin, or rotenone. Inhibitors of complex IV, nitric oxide 
synthase, the NADPH oxidases, xanthine oxidases, the 
mitochondrial permeability transition pore, and the mito-
chondrial ATP-sensitive K(+) channel did not change the 
NADH effect on INa. Analogous results were observed in 
cardiomyocytes. Rotenone, mitoTEMPO, and 4’-chloro-
diazepam also blocked the mutant A280V GPD1-L (glyc-
erol-3-phosphate dehydrogenase 1-like) effect on reducing 
INa, indicating a role for mitochondria in BrS caused by 
this mutation. Fluorescent microscopy confi rmed mito-
chondrial reactive oxygen species generation with elevated 
NADH and reactive oxygen species inhibition by NAD (+). 
The authors conclude that altering the oxidized to reduced 
NAD (H) balance can activate mitochondrial reactive oxy-
gen species production, leading to reduced INa. This sig-
naling cascade may help explain the link between altered 
metabolism, conduction block, and arrhythmic risk87,88.
 FINAL CONSIDERATIONS
We think that this review contributes in a play-
ful, clear and original manner to understanding the sig-
nifi cance of the sodium channel in the study of heart
functioning, mainly in relation to conductibility and drom-
otropism and the different phenotypes subsequent to the 
SCN5A gene mutations, in the fi eld of Health Sciences. In 
spite of this being a review paper, it allows to understand 
the basic electrophysiology and clinical consequences of 
genetic mutations.
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Resumo:
Os mecanismos da excitabilidade celular e de propagação dos sinais elétricos no músculo cardíaco 
são de grande importância funcional e patológica.  O coração é composto por três tipos de músculo: 
atrial, ventricular e das fi bras especializadas excitatórias e condutoras. Do ponto de vista fi siológico e 
fi siopatológico os estados conformacionais do canal de sódio constitui-se um importante aspecto para 
o diagnóstico e tratamento de doenças cardíacas. A descrição dos estados funcionais do canal de sódio 
(fechado, aberto e inativado) e sua estrutura ajudam a compreensão dos processos de regulação cardí-
aca. Há áreas no músculo cardíaco com diferenciação anatômica e funcional que possuem automatis-
mo submetendo as demais fi bras ao seu próprio ritmo. A frequência dessas áreas (marca-passo) pode 
ser alterada por  modifi cações iônicas, pela temperatura e, especialmente, do sistema autonômico.  Já 
a excitabilidade é a propriedade que tem o miocárdio de reagir quando estimulado. A outra propriedade 
elétrica é a condutibilidade, que se caracteriza por um processo de condução e ativação, no qual o 
potencial de ação, pela ei do tudo ou nada,  percorre todo o coração. Destaca-se que o relaxamento 
do coração também é um processo ativo, dependente de gasto energético e de ações iônicas e enzi-
máticas específi cas, destacando o papel dos canais de sódio no processo funcional. Nos aspectos das 
mutações no gene que codifi ca o canal rápido de sódio (gene SCN5A), este é responsável por vários 
fenótipos, tais como a síndrome de Brugada; a fi brilação ventricular idiopática, a miocardiopatia dilata-
da; a síndrome de repolarização precoce; a fi brilação atrial familiar; a síndrome do QT longo variante 3; 
as contrações ventriculares ectópicas multifocais originadas nas arborizações de Purkinje; o distúrbio 
progressivo de condução intraventricular cardíaco (doença de Lenègre); a síndrome da morte súbita do 
recém-nascido; a síndrome do nódulo sinusal doente; a síndrome da morte súbita noturna inesperada, 
entre outras alterações do canal de sódio  com sobreposições clínicas, as chamadas “overpping”. Por 
fi m, parece ser apropriado considerar a “síndrome do canal de sódio” (mutações no gene da subunida-
de α do canal de sódio, gene SCN5A) como uma entidade clínica única que pode manifestar-se com 
um amplo espectro de fenótipos e assim, prover um melhor entendimento destas síndromes cardíacas 
e potencial desfecho para seu tratamento clínico.
Palavras-chave: síndromes arrítmicas, potencial de ação, a despolarização, da condução cardíaca.
